Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM. The median OS of 15 months suggests that the rate of clinical benefit may be larger than the modest response rate.